Home Blog Page 2098

HKPC “SME ReachOut: FUND Fair plus Tech Sourcing 2025” Opens

By
Advertorial Desk
-

One-stop Resource Platform to Help SMEs Explore New Markets

Sunny TAN: Empowering Enterprises to Enhance Competitiveness and Discover New Growth Areas

HONG KONG, Oct. 17, 2025 /PRNewswire/ — The Hong Kong Productivity Council (HKPC) and the Trade and Industry Department (TID) jointly organised the annual flagship event “SME ReachOut: FUND Fair plus Tech Sourcing 2025” (referred to as “the Fair”), which officially opened yesterday at the HKPC Building. The two-day Fair aims to assist the SMEs to grasp the latest trends in digitalisation and market expansion, providing ongoing support for business development. The opening ceremony was officiated by Mr Algernon YAU Ying-wah, JP, Secretary for Commerce and Economic Development; Hon Sunny TAN, Chairman of HKPC; Mr Aaron LIU Kong Cheung, JP, Director-general of TID; and Mr Mohamed Din BUTT, MH, Executive Director of HKPC. Now in its fifth edition, the Fair has registered with over 6,000 pax this year, reflecting strong industry demand for Government funding and technology upgrade services.

HKPC and TID jointly organised the annual flagship event "SME ReachOut: FUND Fair plus Tech Sourcing 2025".
HKPC and TID jointly organised the annual flagship event “SME ReachOut: FUND Fair plus Tech Sourcing 2025”.

The Fair has been serving as a one-stop resource matching platform for nearly 360,000 local SMEs. This year’s Fair, themed “FUND Tech Go”, gathers over 80 exhibitors from Government funding bodies, technology vendors, and scheme implementation agencies. It features five thematic zones—Grab Fund, Go Global, Go Green, Go AI & Digital, and eCommerce LIVE & RetailTech, with a focus on three emerging areas: artificial intelligence (AI), new retail technology, and intellectual property (IP) branding. This helps enterprises capitalise on critical development opportunities such as “Market Expansion”, AI, digital transformation, cross-border e-commerce, and IP. Business representatives from Chinese Mainland and various ASEAN countries have also been invited to share practical insights in the Market Expansion (Go Global) zone, offering strategic guidance for business expansion.

Hon Sunny TAN, Chairman of HKPC, remarked in his opening address that, “Facing rapid shifts in the global economic landscape, this year’s Policy Address calls for further support for SMEs, assisting them in enhancing competitiveness, expanding overseas markets, and exploring new growth areas. As a staunch supporter of SMEs, HKPC will actively align with Government policies to promote collaboration between Mainland and Hong Kong enterprises. Leveraging Hong Kong’s role as a connector, HKPC aims to assist businesses, brands, technologies, and services from both regions in entering new regions and achieve win-win outcomes. HKPC also provides comprehensive support for SME upgrading and transformation through promoting technology transfer and Government funding schemes, as well as offering professional consultancy services.”

Mr Algernon YAU Ying-wah, JP, the Secretary for Commerce and Economic Development, stated in his address that the Government has been supporting SMEs in transformation and upgrading, expanding into overseas markets, and assisting SMEs in enhancing operational efficiency and market competitiveness by leveraging new technologies. Mr Yau said he hoped that through this large-scale annual event today, SMEs will gain an understanding of the resources provided by the Government, grasp the latest market trends, promote the application of new technologies, assist them with digital upgrading and transformation, and ultimately enhance their competitiveness in the digital economy era. He encouraged SMEs to leverage the various support measures outlined in this year’s Policy Address, accelerate their upgrading and transformation, and explore diversified markets to face current challenges and opportunities. He would also like to thank HKPC for their efforts in operating the “SME ReachOut” and organising this Fair. The Government will continue to maintain close communication with the industry, providing comprehensive assistance from various aspects to jointly promote the better development of Hong Kong SMEs.

First-ever Immersive Digital Experiences, Helping SMEs to Master Digital Marketing and Market Expansion Strategies

This year’s Fair features over 80 exhibitors and 12 thematic seminars, enabling attendees to exchange ideas with experts and gain comprehensive insights into key areas such as technology applications, digital transformation, cross-border e-commerce, Government funding, and ESG. For the first time, the Fair introduces an immersive digital experience, enabling SMEs to explore practical solutions through interactive demonstrations by “AI digital humans,” KOL live streaming, and cross-border e-commerce platform showcases. The event also brings together local and overseas business development organisations, with business representatives from Chinese Mainland and various ASEAN countries sharing the latest intelligence on overseas market expansion.

The Fair features a wide range of technology and business service exhibitors, offering comprehensive support to SMEs from AI and IP branding to new market expansion. Regarding AI applications, local enterprise Mastersound Limited specialises in AI voiceprint technology. It has developed an “AI Digital Human” service that can generate multilingual video and audio content for SMEs to create foreign language promotional videos, including Arabic, to effectively explore emerging markets. For IP branding, Innovative Entrepreneurship Association (IEA) actively promotes local IP design internationally by organising field trips, helping local IPs exhibit in Chinese Mainland and overseas, and facilitating cooperations with mainland toy manufacturers to jointly expand into emerging markets, thereby enhancing synergy. To further regional cooperation, the Qianhai Authority has established the Qianhai International Liaison Services and Investment Co., Ltd in Hong Kong as its official window to serve as a vital bridge for Hong Kong enterprises to expand their markets. The platform continuously promotes economic collaboration between Shenzhen and Hong Kong and has provided comprehensive support to a cumulative 10,000 enterprises and talents to date.

An onsite one-stop Government funding consultation service is available, allowing enterprises to engage directly with the “SME ReachOut” team for up-to-date information on key schemes such as the BUD Fund, E-Commerce Easy, and the New Industrialisation Funding Scheme. Since its launch in 2020, SME ReachOut has provided comprehensive support for the sustainable development of SMEs, serving over 79,000 individuals and handling more than 40,000 cases to date.

HKPC cordially invites all SMEs to register and participate in this free event. By engaging with a wealth of onsite resources including Government funding information, one on one expert consultations, and practical case study sharing, businesses can explore actionable solutions to strengthen resilience and enhance competitiveness. SME representatives are encouraged to attend in person to gain deeper insights into funding schemes and technology application strategies, empowering them to expand their international presence and uncover new growth opportunities.

Download link for hi-res photos:

https://www.dropbox.com/scl/fo/cy2vu2awu57cpu8nqh5uz/ANwNW1vfJhA1Y6_asY3_6Ew?rlkey=xetro3nddg89cen6th8y3c26g&st=o0rg1tnd&dl=0

About Hong Kong Productivity Council 

The Hong Kong Productivity Council (HKPC) is a multi-disciplinary organisation established by statute in 1967, to promote productivity through relentless drive of world-class advanced technologies and innovative service offerings to support Hong Kong enterprises. As a nationwide leader in innovative, market-driven research and development (R&D), specialising in leading technologies and all-rounded manufacturing services, HKPC promotes new industrialisation in Hong Kong and the Chinese Mainland and facilitates the development of new productive forces, leveraging innovation and technology (I&T), as well as bolstering Hong Kong to be an international innovation and technology centre and a smart city. The Council offers comprehensive innovative solutions for Hong Kong industries and enterprises to enhance competitiveness. To further support businesses in expanding into global markets, HKPC has established “The Cradle – Go Global Service Centre”, providing essential services to address businesses’ needs in product development, technology, manufacturing, and management, empowering enterprises to successfully go global. The Council partners and collaborates with local industries and enterprises and world-class R&D institutes to promote technology transfer, product innovation, and commercialisation through product innovation, technology transfer, creating value for industries. HKPC’s world-class R&D achievements have been widely recognised over the years, winning an array of local and overseas accolades.

In addition, HKPC offers SMEs and startups immediate and timely assistance in coping with the ever-changing business environment and strengthens talent nurturing and Hong Kong’s competitiveness with FutureSkills training for enterprises and academia to enhance digital capabilities and STEM competencies.

For more details, please visit HKPC website: www.hkpc.org. 

Media Inquiry:

Corporate Communications Unit
Corporate Development Division
Hong Kong Productivity Council
Tel: +852 2788 5833
Email: mediacentre@hkpc.org 

Chance Communications
Mandy Chan / Tommy Yuen
E: mandy@chancecomm.com / tommy@chancecomm.com
T: +852 2509 3123

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

By
Advertorial Desk
-
  • New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide
  • Intention to pursue a Hong Kong initial public offering (IPO) to expand access to global capital and innovation through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX)
  • Name change to be effective following shareholder approval, which is expected at the Extraordinary General Meeting (EGM) on October 24, 2025
  • Pending acquisition of AM712 (also known as ASKG712), to be named VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, and a more potent molecule that could potentially provide more effective and durable treatment benefits for patients with wet AMD and DME than current standard of care. The pending acquisition will be completed by a newly formed subsidiary Visara, Inc., a clinical-stage biopharmaceutical company focused on the development of ophthalmic therapeutics for serious eye disorders
  • Appointment of Mr. Kyler Lei as Chief Financial Officer, bringing significant expertise in Hong Kong and global capital markets

ROCKVILLE, Md., Oct. 17, 2025 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide, yesterday announced its new business model, focused on its global capabilities built to accelerate access to innovative medicines and to enable broad strategic growth. The Company announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences.

The Company also announced the pending acquisition of VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) than current standard of care. The pending acquisition will be made by a newly formed subsidiary, Visara, Inc. (Visara), a clinical-stage biopharmaceutical company focused on developing ophthalmic therapeutics for serious eye disorders, and is expected to be completed later this month.

In addition, the Company reaffirmed its previously announced givastomig investment plans as part of its new strategy.

Mr. Kyler Lei has been named Chief Financial Officer (CFO) of I-Mab, bringing significant expertise in the Hong Kong and global capital markets.

The Company sees a significant growth potential from the Asia Pacific originated biopharma innovations. Confidence in this opportunity comes from emerging trends showing that the Asia Pacific region has generated more than 30% of global biopharma assets under development, and has achieved more than $80B in deal value through collaborations with leading multi-national pharmaceutical organizations. In addition, the Asia Pacific biopharmaceutical ecosystem has become increasingly agile and efficient, with significantly lower clinical trial costs and faster patient enrollment than the global median, while maintaining high quality standards1. 

“We believe we are entering a new era of rapid growth in the global biotech economy, driven by greater innovation capability in China and Asia and a resurgence of investment in high growth international markets across Asia. With our new business model, we are uniquely positioned to strategically create significant value for patients and investors,” said Mr. Fu Wei, Executive Chairman of I-Mab. “Through the strategic insight of our expanded Board, backing by CBC Group, Asia’s largest dedicated healthcare asset management firm, and our dual listing strategy, I-Mab is ideally placed to partner with leading global innovators to identify and accelerate high-value assets. The proposed dual listing on both NASDAQ and HKEX is a key element of our global growth strategy. This move will enable us to broaden and diversify our investor base, and enhance trading liquidity and access to capital, while strengthening our presence with key stakeholders in the rapidly growing Asian market.”

“2025 has been a time of significant progress for I-Mab. Presentation of compelling Phase 1b givastomig combination data reinforced our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for gastric cancer and drove our plans to initiate a global randomized Phase 2 study, expected to begin in Q1 2026. In addition, the Company recently secured additional capital, and has attracted seasoned biotech executives to the Board of Directors and Scientific Advisory Board,” said Sean Fu, PhD, Chief Executive Officer (CEO) of I-Mab. “With the strong foundation from our work on givastomig, and excellent progress this year, we are optimistic about moving forward with our new strategy. Our new global platform allows us to uphold our commitment to value creation by realizing the full potential of innovative medicines and improving the lives of patients.”

The NovaBridge Business Model and Pipeline

The Company intends to partner with leading innovators to identify and accelerate high-value assets. Our model integrates rigorous asset selection, bespoke translational strategies, and efficient clinical execution. With the backing of CBC Group, we leverage deep local insights and global capabilities to develop the most promising drug candidates across a range of therapeutic categories.

The Company will utilize a “hub-and-spoke” model to create and advance specialized subsidiary companies (spokes) which maintain operational focus and agility. By focusing each spoke on a specific asset or therapeutic area, the Company can optimally manage risk and create value through potential partnering transactions.

Pipeline:

  • Givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, is in Phase 1b clinical trials for the potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. A global, randomized Phase 2 study is planned, with the enrollment of the first patient targeted in Q1 2026. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.
  • Ragistomig is an anti-PD-L1 X 4-1BB bispecific antibody. Built on Phase 1 clinical data, an ongoing Phase 1b study designed to expand the therapeutic index is expected to yield results in 2H 2026. The program is being jointly developed with ABL Bio.
  • Uliledlimab targets CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. Progression free survival (PFS) data are expected in 2H 2026 from an ongoing randomized Phase 2 trial evaluating uliledlimab + toripalimab compared to pembrolizumab alone or toripalimab alone. I-Mab owns worldwide rights to uliledlimab outside of Greater China.

VIS-101, to be acquired by Visara, a newly formed I-Mab subsidiary, under the new business model, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development

  • VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME, and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.
  • Acquisition will be completed by a newly subsidiary, Visara. Visara, a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics, will be launched with an approximately $37M capital infusion from I-Mab and the contribution of certain rights by AffaMed Therapeutics (HK) Limited. The capital contributions to Visara and its acquisition of VS-101 (collectively, the Transactions) are cross-conditioned, and are expected to close later this month. The Company has also signed a separate termsheet with Everest Medicines (HKEX 1952.HK) to potentially out-license greater China rights for VIS-101 and collaborate on global clinical development. Following completion of the Transactions, I-Mab will be the majority shareholder of Visara, and Visara will control global rights to VS-101.
  • Visara is led by Co-Founder and Executive ChairmanEmmett T. Cunningham, Jr., MD, PhD, MPH. Dr. Cunningham has been a physician, innovator, entrepreneur, and investor for more than 25 years, formerly serving as Senior Managing Director at Blackstone Group L.P. and Managing Director at Clarus Ventures, LLC. Dr. Cunningham is also an internationally recognized specialist in infectious and inflammatory eye disease with over 450 co-authored publications.

“VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities,” said Dr. Cunningham, Co-Founder and Executive Chairman of Visara. “Leveraging the speed, quality, and unique advantages of dedicated teams in North America and Asia, Visara will seek accelerated global clinical development and regulatory approvals.”

Organizational Overview

The Company will build on the strength of the I-Mab Board, led by Mr. Fu Wei, Executive Chairman, including the expanded Scientific Advisory Board and new Research and Development Committee. The Executive Leadership Team will include Sean Fu, PhD, Chief Executive Officer; Phillip Dennis, MD, PhD, Chief Medical Officer; Kyler Lei, Chief Financial Officer; and Claire Xu, MD, PhD, Senior Vice President, Clinical Development.

Kyler Lei has been appointed as the Chief Financial Officer of I-Mab, effective October 16, 2025. Kyler is a global capital markets and investor relations professional with extensive experience in healthcare, equity research, corporate communications, corporate finance and strategy. Kyler will be primarily responsible for overseeing overall financial strategy and management, corporate finance and capital markets, corporate development and operations. Prior to joining I-Mab, Kyler served as Deputy General Manager and Head of Capital Markets at Sino Biopharmaceutical Limited (HKEX: 1177.HK).

“I am enthusiastic about starting on this new chapter with Kyler, and leveraging his expertise in global capital markets and financial strategy to make our new business model a resounding success,” said Dr. Fu, CEO.

Dr. Fu added, “I would like to extend our gratitude to Joseph Skelton for his tremendous contributions in shaping I-Mab’s success. We wish him all the best in his future endeavors.”

Business Update Webinar

The Company will review its new business model, strategic focus and upcoming milestones by webcast on Thursday, October 16, 2025, and Friday, October 17, 2025

Webcast and Conference Call Details:

In English:

In Chinese:

A replay of the webinar will be accessible on the Events page of the Company website for 90 days.

Sources

1.  Proprietary McKinsey Research Report, 2025

About I-Mab

I-Mab (NASDAQ: IMAB) is a global biotechnology platform company committed to accelerating access to innovative medicines. We combine deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, I-Mab enables transformative therapies to progress rapidly from discovery toward patients in need. Following this business model change, the Company announced that it intends to change its name to NovaBridge Biosciences on October 16, 2025, which is subject to Extraordinary General Meeting (EGM) approval on October 24, 2025.

The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.

Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. I-Mab is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, I-Mab owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.

VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a large, randomized, dose-ranging Phase 2 study for wet AMD. Following completion of the Transactions, I-Mab will be the majority shareholder of Visara, and Visara will control global rights to VIS-101.

For more information, please visit https://www.i-mabbiopharma.com and follow us on Linkedin(https://www.linkedin.com/company/i-mab/posts/?feedView=all).

Dual Listing on NASDAQ and Hong Kong Stock Exchange

More information on I-Mab’s intention to pursue an IPO in Hong Kong and seek a listing on the Hong Kong Stock Exchange (HKEX) will be forthcoming.

The timing, size, structure, and specific terms of the Proposed Offering have not been determined and remain subject to market conditions and approvals by the relevant regulatory authorities, including the HKEX (and the Listing Committee) and any other applicable regulatory bodies. There can be no assurance as to whether, when, or on what terms the Proposed Hong Kong Listing will be completed.

Subject to regulatory and corporate approvals, the Company currently expects to maintain its existing listing of American Depositary Shares (ADSs) on NASDAQ and to pursue a dual listing in the US and Hong Kong. Final decisions will be made in light of market conditions and regulatory feedback.

This announcement is for information purposes only and does not constitute, or form part of, any invitation or offer to acquire, purchase or subscribe to any securities of the Company. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential benefits of the new corporate strategy, intention to pursue a Hong Kong IPO, potential for a new dual NASDAQ Global Market and Hong Kong Stock Exchange (HKEX) listing, new leadership appointments, the pending VIS-101 acquisition, and the planned capitalization of Visara, the expected approval of shareholder proposals at the upcoming EGM, the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates, the strategic and clinical development of I-Mab’s drug candidates, including givastomig and VIS-101; anticipated clinical milestones and results, and related timing; and the Company’s anticipated cash runway. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in I-Mab’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.

I-Mab Investor & Media Contacts

PJ Kelleher

 Kyler Lei

LifeSci Advisors

 I-Mab

+1-617-430-7579

 +1-240-745-6330

pkelleher@lifesciadvisors.com 

 kyler.lei@imabbio.com 

IR@imabbio.com 

Tomorrowland 2025: Overcoming Adversity with Unity

By
Advertorial Desk
-

SHENZHEN, China, Oct. 17, 2025 /PRNewswire/ — Tomorrowland is more than just a music festival – it’s a global gathering where hundreds of thousands of “People of Tomorrow” return to Boom, Belgium each summer to celebrate electronic music, creativity, and connection. Its guiding spirit – Live Today, Love Tomorrow, Unite Forever – has long symbolized collective unity.

In 2025, that spirit was truly tested. Just days before opening, an unexpected fire severely damaged the iconic Orbyz Mainstage, raising serious concerns about whether the event could proceed. With crews already on site and attendees from around the world on the way, the challenge was immense.

PIXELSCREEN.eu, Tomorrowland’s trusted production company, took the lead in on-site coordination and visual recovery. Backed by INFiLED’s technical expertise and other suppliers, the team worked efficiently to minimize visual disruption and preserve the festival’s immersive atmosphere.

This story is not about one company – it’s about what happens when a production community refuses to let the music stop. From emergency reconstruction to visual continuity, and from the Mainstage to other immersive venues, everyone played a part. This is how Tomorrowland 2025 became unity in action.

Rebuilding the Heart of the Festival

The Orbyz Mainstage at Tomorrowland 2025 was envisioned as a cosmic glacier – towering over 50 m tall and 140 m wide, with glowing surfaces and crystalline forms that defined the festival’s visual centerpiece.

During a final pyrotechnic rehearsal, flames erupted within the structure. Fortunately, no one was injured, but nearly 75% of the Mainstage was destroyed – yet cancellation was never an option. Organizers released a statement mourning the loss of “a living, breathing world” while reaffirming their commitment to press on.

PIXELSCREEN.eu immediately coordinated recovery efforts. As CEO Frank Verstraeten later recalled, “The original Mainstage was destroyed by fire, and we had less than 24 hours to rebuild. This was only possible with equipment that was extremely reliable and could be installed very quickly.”

Within a very tight window, on-site teams reassembled a clean, modern substitute Mainstage – 8 m high and 70 m wide – using nearly 700 LED cabinets. The rebuild required logistical precision and technical flexibility, supported by features such as:

  • Magnesium-alloy frames provide rigidity and stability for precise, repeatable setup.
  • Magnet-assisted assembly enables quick, effortless installation.
  • Positioning pins ensure fast, accurate alignment.
  • Fast-lock system allows one-hand operation for instant locking.
  • AR Series touring carts offer robust storage and transport, in single or double-stack sizes, fitting standard trucks.

Tomorrowland 2025
Tomorrowland 2025

Hundreds of panels went up within hours. The installation, paired with NovaStar‘s COEX 5G control system, which supports 5G signal transmission, allowed the control crew to adjust visual output to fit the improvised stage layout, keeping everything running smoothly. Though simpler in form, the rebuilt stage still delivered full sensory impact – vibrant screens, synced lighting, and powerful sound – proving Tomorrowland’s spirit remained undimmed.

Beyond the Mainstage – Visual Continuity Across the Festival

Even as crews worked tirelessly on Orbyz, dozens of stages across the festival continued delivering immersive experiences powered by LED visuals and tight execution.

  • Freedom Stage

The Freedom Stage was among the most technically ambitious. Known for its vast enclosed design, the 2025 edition featured the “Floating Sky” – a kinetic LED ceiling installation that shifted shape and light above the crowd. Built using INFiLED’s lightweight and transparent AMT panels featuring 70% transparency and a triangular module layout, the structure delivered layered visuals while allowing stage lighting, wind, and sound to pass through. The result was a mesmerizing, space-like ambiance that transformed continuously throughout each set.

Freedom Stage
Freedom Stage

  • The Great Library

A recently redesigned domed venue, The Great Library used curved LED screens integrated along its arches and backdrop to display animated visuals and live camera feeds. Built with INFiLED’s AR panels – capable of ±10° cabinet curvature – the installation wrapped seamlessly around the dome, creating an intimate and cinematic atmosphere.

The Great Library
The Great Library

  • CORE Stage

Tucked into Tomorrowland’s forested area, the CORE stage returned in 2025 with a distinctive visual identity – a large, split-face screen centerpiece surrounded by natural scenery. The immersive design offered a meditative counterpoint to the adrenaline-fueled main areas.

CORE Stage
CORE Stage

This widespread deployment underscored the role LED visuals played – not as mere decoration, but as a binding agent across Tomorrowland’s production fabric. Throughout the weekends, the show never paused – and the visual magic never faded.

A Triumph of Unity

“PIXELSCREEN.eu has been exclusively providing all video screens for Tomorrowland for 22 years, non-stop,” said Frank Verstraeten.

Tomorrowland 2025 will be remembered not for the fire, but for how the event came together. In a very short time, engineers, crews, designers, and planners rebuilt what months had built, proving that unity and shared purpose can overcome any disruption.

“Unite Forever” – that wasn’t just words on a screen. In 2025, it became living proof.

Email: info@infiled.com 

Website: www.infiled.com 

Meiji Sweets Ambassador FRUITS ZIPPER Promotes Meiji Gummy “Poifull” in Taipei on First Day of Group’s Asia Tour

By
Advertorial Desk
-

– Poifull Handed Out to Fans to Make Their Day “A Little Happier” –

TOKYO, Oct. 17, 2025 /PRNewswire/ — Meiji Co., Ltd., headquartered in Tokyo, collaborates with the seven-member idol group FRUITS ZIPPER, which is Meiji Sweets Ambassador, on the group‘s first Asia Tour called “FRUITS ZIPPER 1st ASIA TOUR 2025.” Their aim for the world from Harajuku, Tokyo, is based on the same passion with the company’s hope to help people around the world feel their daily life “a little bit happier.” On October 8 (Wed.), at the group’s concert venue in Taipei, Taiwan, the company aired a promotional video and handed out Poifull, small-sized sugar-coated gummies, to all fans at the site.

Images: https://kyodonewsprwire.jp/release/202510147075?p=images 

In front of a panel featuring the autographs of the FRUITS ZIPPER members, a large number of fans gathered and took pictures with Poifull in their hands. The company found the venue had a vibrant atmosphere.

Mana Manaka of FRUITS ZIPPER said, “I found a lot of Meiji products at convenience stores in Taipei. I‘d never seen some of them in Japan and it was really fun to see them. In Japan, there are many more Meiji sweets products. Among them, Poifull, with its happy look and taste, can be carried easily and shared. So I hope everyone enjoys Poifull with their friends.” She also expressed her enthusiasm about promoting Meiji products abroad as a “Meiji Sweets Ambassador.”

Free samples of Poifull will also be handed out at the following concert venues in Shanghai, China, and Seoul, South Korea.

FRUITS ZIPPER 1st ASIA TOUR 2025 Schedule
October 8 (Wed.) Taipei
November 8 (Sat.) and 9 (Sun.) Shanghai
November 29 (Sat.) Seoul

About Poifull

The joyful, soft-textured gummy Poifull is a power source that can help everyone smile. There are four popular flavors in one packet: raspberry, lemon, green apple and grape.

Official websites:
https://www.meiji.co.jp/sweets/candy_gum/poifull/
https://www.meiji.com/global/ 

JNJ International Accelerates Global Expansion with KOTRA: Launches Buyer Discovery Project in Five Countries

By
Advertorial Desk
-

SEOUL, South Korea, Oct. 17, 2025 /PRNewswire/ — JNJ International, a global automotive parts distributor, is accelerating its global market expansion.

Centered on Hyundai and Kia Genuine Parts, the company has established stable supply chains across major regions and is now working with KOTRA on a new buyer discovery project across five countries to strengthen its global partnership network.

Founded in 2023, JNJ International specializes in the distribution and export of Hyundai and Kia Genuine Parts, along with various aftermarket products, to partners in Europe, the Middle East, Asia, and the Americas.

Through this project, the company aims to build long-term partnerships with leading distributors in each region and enhance the global reputation of Korean automotive parts.

JNJ plans to continue expanding its brand presence by participating in international trade fairs, developing new partnerships, and building a more efficient logistics infrastructure for stable supply operations.

RAVEN2, NETMARBLE’S BRUTAL DARK FANTASY MMORPG, ENTERS FINAL COUNTDOWN TO GLOBAL LAUNCH

By
Advertorial Desk
-

SEOUL, South Korea, Oct. 17, 2025 /PRNewswire/ — Netmarble, a renowned developer and publisher of high-quality games, is gearing up for the global launch of its ultimate dark fantasy MMORPG Raven2, which will officially launch on October 22 at 1AM (UTC) for both mobile and PC platforms. Pre-download begins October 21 at 3AM (UTC).

Raven2 will be available in 150 countries and support 16 languages, ranging from English, Thai to French, Indonesian, and more. The global version of Raven2 will have three major regions: North America, Southeast Asia & Oceania, and Europe, and each region includes two Worlds and twelve servers, with players free to select any server within their region. 

To celebrate the launch, Raven2 is hosting a special event offering Crystals. Players can earn Crystals by simply leveling up, while the top 100 players per server will compete for one million Crystals. A special tax fund of one million Crystals will be pre-deposited into each server’s Market, claimable through the guild activity. 

Players can still pre-register on Google Play and the App Store, or wishlist the game on the Epic Games Store. Pre-registered players will receive exclusive rewards including a heroic grade Holy Garment and a special package. 

Powered by Unreal Engine, Raven2 showcases unrivaled graphics, and a vast universe set in a dark fantasy realm where players become a member of the Special Corps bearing the “Cursed Stigma.” As they investigate strange and perilous phenomena unfolding across the world, they embark on a journey to vanquish demons and uncover the secrets behind the world’s fate. Raven2‘s large-scale guild-based battles are all hallmarks of a truly immersive, high-quality MMORPG experience. 

For more information, visit the official website and follow Raven2 on YouTube, Facebook, and Discord to stay updated. 

About Netmarble Corporation
Founded in Korea in 2000, Netmarble Corporation is a leading global game developer and publisher. Through acclaimed franchises and strategic partnerships with top-tier IP holders, the company delivers innovative and engaging gaming experiences to audiences worldwide. As a parent company of Kabam, SpinX Games, Jam City, and a major shareholder of HYBE and NCSOFT, Netmarble’s diverse portfolio includes Solo Leveling:ARISE, Seven Knights Idle Adventure, Tower of God: New World, Lineage 2: Revolution, MARVEL Future Fight, Ni no Kuni: Cross Worlds and The Seven Deadly Sins: Grand Cross. More information can be found at http://company.netmarble.com.

SIMAGIC at SimRacing Expo 2025: A Triple Reveal

By
Advertorial Desk
-

SIMAGIC Showcases Next-Generation Simulation at SimRacing Expo 2025
October 17–19, 2025 | Hall 3, Booth BC6 | Messe Dortmund, Germany

DORTMUND, Germany, Oct. 17, 2025 /PRNewswire/ — SIMAGIC, a global leader in high-performance sim racing hardware, is set to make a major impact at SimRacing Expo 2025 with its most comprehensive showcase to date. From October 17–19, visitors can explore cutting-edge products, take part in on-site competitions, and meet some of the most recognized creators in the sim racing community.

SIMAGIC at SimRacing Expo 2025
SIMAGIC at SimRacing Expo 2025

A Showcase of Innovation
At the heart of the booth, SIMAGIC will unveil its latest technologies — including the P700 Pedals, EVO Ultra Wheelbase, and the Zeus Formula Steering Wheel. Each product embodies the brand’s pursuit of realism, precision, and modular versatility, offering racers an unprecedented level of control and immersion.

Special Guests: Super GT and Jackzer
Fans will have the chance to meet two of the scene’s most influential voices.

Super GT (Steve) — Known globally for his blend of humor, high-level racing, and real-world competition in the Nürburgring Langstrecken-Serie (NLS), he brings unique insights into the connection between simulation and motorsport.

Jackzer — Recognized for his authenticity and engaging approach to iRacing content, Jack’s focus on sim racing psychology and driver mindset adds a refreshing new perspective for enthusiasts.

Time Attack Challenge: Race. Compete. Win.
Visitors can test their skill behind the wheel in the SIMAGIC Time Attack Challenge. The fastest laps of the weekend will earn exclusive SIMAGIC prizes, with a live leaderboard tracking every contender throughout the event.

Live Content & Interactive Experiences
The excitement doesn’t stop at the booth. Portions of the event will be streamed live, featuring behind-the-scenes moments, commentary, and guest appearances from creators and SIMAGIC engineers.

Join the Experience
Whether you’re a competitive racer, content creator, or first-time visitor, Hall 3, Booth BC6 is the destination for anyone passionate about sim racing innovation. Experience the technology shaping the future of virtual motorsport — only with SIMAGIC.

Keep Racing.

/C O R R E C T I O N — Siemens Healthineers/

By
Advertorial Desk
-

In the news release, NUH And NUS Launch New Molecular Imaging And Theranostic Centre To Strengthen Patient Care And Research, issued 16-Oct-2025 by Siemens Healthineers over PR Newswire, we are advised by the company that the headline and 1st paragraph have been updated; all instances of Molecular Imaging and Theranostic Centre have been updated to Molecular Imaging and Theranostics Centre; all instances of NUS CIRC have been updated to NUS Medicine. The complete, corrected release follows:

NUH And NUS Launch New Molecular Imaging And Theranostics Centre To Strengthen Patient Care And Research

  • Powered by Singapore’s first next-generation total-body PET/CT system, the new facility aims to transform diagnostics, treatment and research in cancer and beyond

SINGAPORE, Oct. 16, 2025 /PRNewswire/ — The National University Hospital (NUH) and the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have jointly launched the Molecular Imaging and Theranostics Centre, a novel integrated clinical, education, research & development facility that brings together advanced diagnostics, targeted therapy and pioneering research. This landmark development is set to transform the way diseases such as cancer are diagnosed, treated and studied, positioning Singapore at the forefront of molecular imaging in Asia.

At the heart of the new centre is Singapore’s first total-body PET/CT (Hybrid Positron Emission Tomography and Computer Tomography) system launched in partnership with Siemens Healthineers, located at the NUH Medical Centre. The next-generation scanner sets a new benchmark in advanced medical imaging and a major step forward in enhancing patient care.

A game-changer for patient care

The total-body PET/CT system represents a significant advancement over traditional PET/CT systems, offering a range of unique benefits to patients that go beyond what conventional PET/CT systems can offer:

Parameters

Total-Body
PET/CT

Conventional
PET/CT

Benefits to Patients

Detection
Sensitivity

~171 cps/kBq

~23 cps/kBq*

More detailed and
accurate diagnostic
information due to ~8
times better detection
sensitivity

Scan Speed

< 5 minutes

8 – 15 minutes

Up to one-third time
savings for patients
undergoing the
PET/CT procedure

Scan Comfort

A single bed
position
(continuous bed
motion)

6 – 14 bed
positions

Only a single patient
position is needed to
acquire images, as the
system enables
continuous bed motion
throughout scan, leading
to better patient comfort.

Scan Throughput

 

Up to 6 patients /
hour

~3 patients / hour

Shorter wait times for
patients due to higher
scanner capacity

Scan Field of

View

106 cm

~25 cm

Greater efficiency due to
wider scanning area, with
> 4 times coverage

Radiation Dose

Up to 80%
reduction

~3.5 to 5 mSv**

Lower exposure to
radiation for patients

Radiotracer Dose

Up to 50%
reduction

6 mCi***

*Counts per second per kilo Bequerel = how many counts of the injected activity are detected

**mSv is an ionising radiation dose measurement unit on health risk to the human body

***mCi is the measurement unit on the amount of radioactivity present

“Total-body PET/CT allows us to capture the whole body in a single bed scan with unmatched clarity,” said Professor Khong Pek Lan, Head & Senior Consultant, Department of Diagnostic Imaging, NUH, and Head, Department of Diagnostic Radiology, NUS Medicine. Professor Khong is also the Director of the NUS Clinical Imaging Research Centre (CIRC), based at NUS Medicine.

“Patients benefit from faster, safer and more precise diagnoses, while our clinicians can harness these insights to explore innovative therapies more effectively. This is a step forward in personalised medicine.”

Unlocking new frontiers in research

Beyond direct patient care, the new centre will also act as a research powerhouse. Researchers now have the capability to observe the real-time movement of tracers throughout the entire body using advanced total-body PET/CT technology. This opens new possibilities for validating next-generation diagnostics and therapies, advancing theranostics – a fast-emerging field that combines diagnostic imaging with targeted therapy. 

Theranostics enables clinicians to first identify disease using a specific diagnostic tracer, and to deliver targeted radiation directly to the very same cancer cells, once suitable molecular targets are identified. This serves to destroy them while sparing most of the healthy tissues.

The ability to conduct such comprehensive studies within a clinical setting will accelerate the development of practice-changing approaches that could become future standards of care. It also strengthens Singapore’s position as a hub for global collaborations and translational research.

NUH, NUS Medicine and industry partner Siemens Healthineers have formalised a Memorandum of Understanding to establish a framework, with the aim of improving patient outcomes through clinical diagnostics, translational research and technological innovations. Together, the partners aim to ensure that the new centre not only benefits patients in Singapore but also drives scientific advancement across Asia.

“Siemens Healthineers is proud to partner NUH and NUS Medicine to launch Singapore’s first total-body PET/CT system, which enables faster, safer, and more accurate diagnostics, while unlocking new frontiers in theranostics and translational research, and shaping the future of healthcare in Singapore and across Asia,” said Ms Siow Ai Li, Managing Director, Siemens Healthineers Singapore, Malaysia and Brunei.

Expected to be operational by early November, the total-body PET/CT scanner will serve around 2,900 patients per year, while also supporting a wide range of clinical trials and research programmes.

The new Molecular Imaging and Theranostics Centre represents a seamless integration between clinical practice and research within the same facility, fostering greater synergy for the benefit of patient care and scientific advancement. Backed by a robust academic and clinical ecosystem, the collaboration will also drive translational research, provide specialised training, and spearhead regional outreach initiatives.

This press release and a press picture is available at
https://www.siemens-healthineers.com/en-sg/press-room/press-releases-sg/shs-nuh-nus-mousigning

The product/features mentioned in this press release is/are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details. The product and features mentioned in this press release are meant for healthcare professionals only.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.

The National University Hospital (NUH) is Singapore’s leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school. Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for.

We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and liver transplant programme in the country. The NUH is a key member of the National University Health System (NUHS), one of three public healthcare clusters in Singapore. For more information, visit www.nuh.com.sg

The National University of Singapore (NUS) is Singapore’s flagship university, which offers a global approach to education, research, and entrepreneurship, with a focus on Asian perspectives and expertise. We have 15 colleges, faculties, and schools across three campuses in Singapore, with more than 40,000 students from 100 countries enriching our vibrant and diverse campus community. We have also established more than 20 NUS Overseas Colleges entrepreneurial hubs around the world.

Our multidisciplinary and real-world approach to education, research and entrepreneurship enables us to work closely with industry, governments, and academia to address crucial and complex issues relevant to Asia and the world. Researchers in our faculties, research centres of excellence, corporate labs and more than 30 university-level research institutes focus on themes that include energy; environmental and urban sustainability; treatment and prevention of diseases; active ageing; advanced materials; risk management and resilience of financial systems; Asian studies; and Smart Nation capabilities such as artificial intelligence, data science, operations research, and cybersecurity. For more information on NUS, please visit http://www.nus.edu.sg/

The NUS Yong Loo Lin School of Medicine (NUS Medicine) is Singapore’s first and largest medical school. Our enduring mission centres on nurturing highly competent, values-driven, and inspired healthcare professionals to transform the practice of medicine and improve health around the world. Through a dynamic and future-oriented five-year curriculum that is inter-disciplinary and inter-professional in nature, our students undergo a holistic learning experience that exposes them to multiple facets of healthcare and prepares them to become visionary leaders and compassionate doctors and nurses of tomorrow. Since the School’s founding in 1905, more than 12,000 graduates have passed through our doors.

In our pursuit of health for all, our strategic research programmes focus on innovative, cutting-edge biomedical research with collaborators around the world to deliver high impact solutions to benefit human lives. The School is the oldest institution of higher learning in the National University of Singapore and a founding institutional member of the National University Health System. It is one of the leading medical schools in Asia and ranks among the best in the world (Times Higher Education World University Rankings 2025 by subject and the Quacquarelli Symonds (QS) World University Rankings by subject 2025). For more information about NUS Medicine, please visit https://medicine.nus.edu.sg/ 

1...2,0972,0982,099...6,463Page 2,098 of 6,463